Eagle Pharmaceuticals announced today that the U.S. FDA has granted seven years of orphan drug exclusivity (ODE) in the U.S., for Bendeka (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. Bendeka is for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). As…